Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer

Lung Cancer

Volumn 41, Issue 1, 2003, Pages 13-20

  Segawa, Yoshihiko ^a   Ueoka, Hiroshi ^b   Kiura, Katsuyuki ^b   Tabata, Masahiro ^b   Takigawa, Nagio ^a,b   Hiraki, Yoshio ^b   Watanabe, Yoichi ^c   Yonei, Toshiro ^d   Moritaka, Tomonori ^e   Hiyama, Junichiro ^f   Hiraki, Shunkichi ^c   Tanimoto, Mitsune ^b   Harada, Mine ^b  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c Japanese Red Cross Okayama Hospital   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^e EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^f Kure Kyosai Hospital   (Japan)

Author keywords

Accelerated hyperfractionated thoracic radiation; Cisplatin; Concurrent chemoradiotherapy; Etoposide; Limited stage small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFICACY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAIR LOSS; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG SMALL CELL CANCER; LUNG TOXICITY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0037783862     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00139-9     Document Type: Article

References (17)

1. Aisner J., Alberto P., Bitran J., et al. Role of chemotherapy in small cell lung cancer: a consensus report of the international association for the study of lung cancer workshop. Cancer Treat. Rep. 67:1983;37-43.
2. Turrisi A.T., Kim K., Blum R., et al. Twice-daily compared once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 340:1999;265-271.
3. Murray N., Coy P., Pater J.L., et al. Importance of timing for thoracic irradiation in the combined treatment of limited-stage small-cell lung cancer. J. Clin. Oncol. 11:1993;336-344.
4. Jeremic B., Shibamoto Y., Acimovic L., et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J. Clin. Oncol. 15:1997;893-900.
5. Takada M., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J. Clin. Oncol. 20:2002;3054-3060.
6. Johnson D.H. Management of small cell lung cancer: current status of the art. Chest. 116:1999;525S-530S.
7. Albain K.S., Crowley J.J., LeBlanc M., et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2580-patient Southwest Oncology Group data base. J. Clin. Oncol. 8:1990;1563-1574.
8. Pignon J., Arriagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327:1992;1618-1624.
9. Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J. Clin. Oncol. 10:1992;890-895.
10. Aupérin A., Arriagada R., Pignon J., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N. Engl. J. Med. 341:1999;476-484.
11. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:1982;649-655.
12. Gregor A., Cull A., Stephens R.J., et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur. J. Cancer. 33:1997;1752-1758.
13. Glisson B., Scott C., Komaki R., et al. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of Radiation Therapy Oncology Group trial 93-12. J. Clin. Oncol. 18:2000;2990-2995.
14. Levitan N., Dowlati A., Shina D., et al. Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J. Clin. Oncol. 18:2000;1102-1109.
15. Bremnes R.M., Sundstrøm S., Vilsvik J., et al. Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J. Clin. Oncol. 19:2001;3532-3538.
16. Noda K., Nishiwaki Y., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346:2002;85-91.
17. Yokoyama A., Kurita Y., Saijo N., et al. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br. J. Cancer. 78:1998;257-262.